News

Press Release

Former BMS Quality Director Joins Pumas-AI Scientists as Head of Quality Assurance and Compliance Amid 3X Growth Period

August 04, 2022 | Press Release

Centreville, Va. (August 4, 2022) - Pumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that Peter J. Miller has joined the organization as Head of Quality Assurance and Compliance. In his role, Mr. Miller will further strengthen and build upon the quality of deliverables and products that Pumas-AI scientists produce, including clinical pharmacology, pharmacometrics, front-end applications, and digital transformation in the pharmaceutical industry.

Miller has extensive knowledge in the development and implementation of quality and compliance systems within the Pharmaceutical, Nutritional, Food & Medical Device industries, most recently as President at Dynamic Compliance Solutions and Director Global Shared Services Quality at Bristol-Myers Squibb. Throughout his 30-year industry tenure, he has also held quality roles at BASF, SmithKline Beecham, and Datascope.

pjmpic

I am grateful to the scientists and founders of Pumas-AI for trusting me with their quality assurance and compliance programs in this highly regulated industry,” said Miller. “Quality and compliance is important for every organization these days, that’s no secret. However, what is impressive is an organization supporting numerous biologics licenses and new drug applications across nearly every therapeutic area with such a clear focus on quality and compliance. I look forward to building upon that.

Strong growth seen at Pumas-AI

In the past two years, Pumas-AI has tripled its size and revenue growth as an organization. Known for helping clients find the shortest path to drug approval, Pumas-AI has grown in the following areas:

  • Clinical pharmacology, including recommending what studies to conduct, when to conduct them, and how to secure study waivers for NDAs, BLAs, ANDAs, and 505(b)(2) applications
  • Pharmacometrics, including modeling and simulation and the use of model-informed drug development (MIDD)
  • Front-end applications, including the first analytical software designed to support high-performance drug development teams with all of the modeling, simulation, and analyses that pharmaceutical scientists need, on one integrated platform

Pumas-AI CEO and former U.S. Food and Drug Administration (FDA) Director, Division of Pharmacometrics, Dr. Joga Gobburu said, “We are committed to empower pharmaceutical, biotech, healthcare companies to treat patients better, and we will continue to achieve this through pharmaceutical modeling and simulation, data-driven analysis, and the most impactful software that the industry has seen in decades.

Learn the latest about Pumas-AI by following us on LinkedIn at https://www.linkedin.com/company/pumas-ai/

About Pumas-AI

Pumas-AI was established by University of Maryland School of Pharmacy faculty members Vijay Ivaturi, PhD, and Dr. Gobburu. At PUMAS-AI, we engineer solutions that empower those on the frontlines of healthcare, from discovery to delivery. With a range of software tools and consultancy expertise, we help scientists, healthcare providers, biotechnology and pharmaceutical businesses as well as regulatory bodies make better decisions. For more information, visit https://pumas.ai/